Mechanism of action 

Learn about the NUCALA (mepolizumab) mechanism of action (MOA) in asthma. The MOA of NUCALA in asthma has not been definitively established.

 

  • transcript

    TEXT ONSCREEN:

    [NUCALA Logo] NUCALA (mepolizumab) Injection 100 mg/mL
    MECHANISM OF ACTION VIDEO
    The mechanism of action of mepolizumab in asthma has not been definitively established.

    TEXT ONSCREEN:

    NUCALA is indicated for the add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype.

    NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.

    NUCALA should not be administered to patients with a history of hypersensitivity to mepolizumab or excipients in the formulation.

    Please review Important Product Information for NUCALA near the end of this video.

    Please see full Prescribing Information for NUCALA at NucalaHCP.com.

     

    TEXT ONSCREEN:

    Eosinophils

    IL-5

    IL-5R alpha

    IL-5R beta common

    Intracellular downstream signaling


    WOMAN NARRATOR:

    Inflammation, an important component of asthma pathogenesis, is mediated by multiple cell types, including eosinophils.

    Eosinophilic inflammation can be reproducibly characterized by blood eosinophil counts.

    Interleukin 5 (IL-5), a major cytokine responsible for eosinophil development, binds to the IL-5 receptor complex expressed on the eosinophil surface.

    Downstream signaling promotes the growth and differentiation, recruitment, activation, and survival of eosinophils.

    TEXT ONSCREEN:

    [NUCALA Logo] NUCALA (mepolizumab) Injection 100 mg/mL

    The mechanism of action of mepolizumab in asthma has not been definitively established.

    WOMAN NARRATOR:

    Mepolizumab is a humanized monoclonal antibody that targets human IL-5 with high affinity and specificity.

    The mechanism of action of mepolizumab in asthma has not been definitively established.

    TEXT ONSCREEN:

    Mepolizumab

    IL-5

    IL-5R alpha

    WOMAN NARRATOR:

    Mepolizumab binds to IL-5, blocking its binding to the alpha chain of the IL-5 receptor complex. This inhibits IL-5 signaling, reducing the production and survival of eosinophils.

    TEXT ONSCREEN:

    IMPORTANT PRODUCT INFORMATION

    May cause hypersensitivity reactions (eg, anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash). Herpes zoster has occurred. Do not stop systemic/inhaled corticosteroids abruptly. Treat pre-existing helminth infections before starting NUCALA. Most common adverse reactions: headache, injection site reactions, back pain, fatigue.

    Please see full Prescribing Information for NUCALA at NucalaHCP.com.

    MALE NARRATOR:

    NUCALA may cause hypersensitivity reactions, such as anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, and rash.

    Herpes zoster has occurred. Consider vaccination if medically appropriate.

    Do not stop systemic or inhaled corticosteroids abruptly.

    Treat pre-existing helminth infections before starting NUCALA.

    Most common adverse reactions were headache, injection site reactions, back pain, and fatigue.

    TEXT ONSCREEN:

    IMPORTANT PRODUCT INFORMATION

    To report SUSPECTED ADVERSE REACTIONS, contact GSK at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    Please see full Prescribing Information for NUCALA at NucalaHCP.com.

    MALE NARRATOR:

    Please see full Prescribing Information for NUCALA at NucalaHCP.com.

    TEXT ONSCREEN:

    1.    NUCALA [package insert]. Durham, NC: GSK; 2023.

    2.    Katz LE, Gleich GJ, Hartley BF, Yancey SW, Ortega HG. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. Ann Am Thorac Soc. 2014;11(4):531-536. 

    3.    Hancox J, Pavord ID, Sears MR. Associations between blood eosinophils and decline in lung function among adults with and without asthma. Eur Respir J. 2018;51(4):1702536.

    4.    Trivedi SG, Lloyd CM. Eosinophils in the pathogenesis of allergic airways disease. Cell Mol Life Sci. 2007;64(10):1269-1289. 

    5.    Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651-659.

    All animations are represented under a licensing agreement with all rights granted for GSK use.

    TEXT ONSCREEN:

    [NUCALA Logo] NUCALA (mepolizumab) Injection 100 mg/mL

    Trademarks are owned by or licensed to the GSK group of companies.
    [GSK logo]

    ©2023 GSK or licensor.

    MPLVID230017 September 2023

    Produced in USA.